NCT00900809已完成1 期
Phase I Study of Adoptive Immunotherapy Using the Natural Killer Cell Line, Neukoplast™(NK-92), for the Treatment of Refractory or Relapsed Acute Myeloid Leukemia
适应症
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 入组人数
- 7
- 试验地点
- 2
- 主要终点
- Determine the safety / maximum tolerated dose of Neukoplast™ (NK-92 cell line for clinical use) in patients with refractory or relapsed acute myeloid leukemia
研究概览
简要总结
NK cells from patients with malignant diseases are often functionally impaired. Their function cannot be fully restored through ex vivo expansion and cytokine activation. In addition, the in vivo administration of cytokines not only expands NK cells but expands polyclonal T cells with no tumor specificity and no known effects.
The utilization of Neukoplast™, as a form of adoptive immunotherapy, offers several advantages. Neukoplast™ represents a uniform cell population with a well-characterized immunophenotype, confirmed strong anti-tumor activity and are easy to grow and expand in culture, so that they can be made available in large numbers for therapeutic delivery.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Patients with refractory/relapse acute myeloid leukemia. Patients must not have received radiotherapy, chemotherapy (with the exception of hydroxyurea which must be discontinued 72 hours prior to therapy) or biological therapy within the preceding 2 weeks of the planned first Neukoplast™ cell infusion and must have recovered from any adverse events due to prior administered agents
- •Assessable disease as measured by laboratory and bone marrow examinations
- •Age: Eighteen years or older
- •Performance status: ECOG ≤ 2 (Appendix A)
- •Serum creatinine < 2 X upper limit of normal
- •Aspartate aminotransferase (AST) < 5 X upper limit of normal
- •Alanine aminotransferase (ALT) < 5 X upper limit of normal
- •Total bilirubin < 3X upper limit of normal
- •Activated partial thromboplastin time (PTT) < 2.5 X upper limit of normal
- •Patients must have left ventricular ejection fraction (LVEF) ≥45 %
- •Females of child-bearing potential must have a negative pregnancy test and all subjects must agree to use an effective method of contraception for up to two weeks after the last infusion of Neukoplast™
- •Ability to give informed consent
- •Life expectancy of greater than 3 months
- •Note: as many of eligible patients will be pancytopenic secondary to their disease or prior therapies hematologic abnormalities will not be used as a criteria for entry or exclusion.
排除标准
- •Patients with acute promyelocytic leukemia
- •Symptomatic central nervous system (CNS) involvement
- •History of congestive heart failure
- •Evidence of severe or uncontrolled systemic diseases (e.g., unstable or uncompensated respiratory, hepatic, renal, or cardiac disease).
- •Uncontrolled, life-threatening infection that is not responding to antimicrobial therapy
- •ECOG performance status >2 (Appendix A)
- •Hepatitis B or C or HIV positive serology
- •History of psychiatric disorder which may compromise compliance with the protocol or which does not allow for appropriate informed consent
- •Patient may not be receiving any other investigational agents
- •Patient is receiving systemic anticoagulation (e.g., warfarin, intravenous heparin. Low dose prophylactic anticoagulation is allowed )
- •Patient undergone autologous or allogeneic stem cell transplantation
- •Concurrent malignancy of solid tumors. Exception: Subjects who have been disease-free for 5 years, or subjects with a history of completely resected non-melanoma skin cancer or successfully treated in situ carcinoma are eligible. Subjects with second malignancies that are indolent or definitively treated may be enrolled.
- •Pregnant or lactating female.
结局指标
主要结局
Determine the safety / maximum tolerated dose of Neukoplast™ (NK-92 cell line for clinical use) in patients with refractory or relapsed acute myeloid leukemia
时间窗: 2016
次要结局
- Evaluate the therapeutic efficacy of Neukoplast™ in patients with refractory or relapsed acute myeloid leukemia(2016)
- Determine the effects of Neukoplast™ on the host immune system, using flow cytometry and the LUMINEX multianalytic profiling system, at different time intervals after the Neukoplast™ infusion.(2016)
- Determine the Neukoplast™ cell phenotype and cytotoxic activity at different time intervals after the Neukoplast™ cell infusion(2016)
- Determine the presence of Neukoplast™ in the bone marrow(2016)
研究者
研究点 (2)
Loading locations...
相似试验
已完成
1 期
Allogeneic Natural Killer (NK) Cell Therapy in Patients With Lymphoma or Solid TumorMalignant LymphomasSolid TumorsNCT01212341Seoul National University Hospital18
Unknown
1 期
Safety and Feasibility of the Use of Natural Killer Cells in Patients With Chronic Myeloid LeukemiaChronic Myeloid LeukemiaNCT03348033Hospital de Clinicas de Porto Alegre5
已完成
1 期
Donor Natural Killer Cells and Donor Stem Cell Transplant in Treating Patients With High Risk Myeloid MalignanciesAccelerated Phase Chronic Myelogenous Leukemia, BCR-ABL1 PositiveAcute Erythroid LeukemiaAcute Myeloid Leukemia Arising From Previous Myelodysplastic SyndromeAcute Myeloid Leukemia in RemissionBlast Phase Chronic Myelogenous Leukemia, BCR-ABL1 PositiveBlasts Under 20 Percent of Bone Marrow Nucleated CellsBlasts Under 20 Percent of Peripheral Blood White CellsHigh Risk Myelodysplastic SyndromeRecurrent Chronic Myelogenous Leukemia, BCR-ABL1 PositiveTherapy-Related Acute Myeloid LeukemiaTherapy-Related Myelodysplastic SyndromeMyelodysplastic SyndromeAcute Myeloid LeukemiaChronic Myelomonocytic LeukemiaAcute Megakaryoblastic LeukemiaNCT01823198M.D. Anderson Cancer Center63
Unknown
2 期
By Using Adoptive Transfer of Autologous NK Cells to Prevent Recurrence of Hepatocellular Carcinoma After Curative TherapyHepatocellular CarcinomaNCT02725996Southwest Hospital, China140
已完成
不适用
atural Killer (NK) Cell Therapy Combined with Hepatic Artery Infusion Chemotherapy (HAIC) in Patients with Advanced Hepatocellular CarcinomaNeoplasmsKCT0004642Vaxcell-Bio20